Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00128115 |
The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Condition | Intervention | Phase |
---|---|---|
Hip Fracture |
Drug: MK0677 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Proprietary Information - Exploratory (Non-Confirmatory) Trial |
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patient has Type II diabetes with any of conditions;
Germany | |
Msd Sharp & Dohme Gmbh | |
Haar, Germany, 85540 | |
Norway | |
MSD (Norge) AS | |
DRAMMEN, Norway, 3011 | |
Spain | |
Merck Sharp & Dohme De Espana, S.A.E. | |
Madrid, Spain, 28027 | |
Sweden | |
Merck Sharp & Dohme (Sweden) AB | |
Sollentuna, Sweden, 192 07 | |
United Kingdom, Hertfordshire | |
Merch Sharp & Dohme Ltd. | |
Hoddesdon, Hertfordshire, United Kingdom, EN11 9BU |
Study Director: | Medical Monitor | Merck |
Study ID Numbers: | 2005_028 |
Study First Received: | August 5, 2005 |
Last Updated: | July 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00128115 |
Health Authority: | United States: Food and Drug Administration |
Hip Fractures Femoral Fractures Fractures, Bone |
Wounds and Injuries Disorders of Environmental Origin Leg Injuries |
Hip Injuries |